Details
| Stereochemistry | MIXED |
| Molecular Formula | C20H28I3N3O9 |
| Molecular Weight | 835.1644 |
| Optical Activity | UNSPECIFIED |
| Defined Stereocenters | 0 / 2 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
CN(CC(O)CO)C(=O)C1=C(I)C(C(=O)N(C)CC(O)CO)=C(I)C(NC(=O)C(CO)CO)=C1I
InChI
InChIKey=YLPBXIKWXNRACS-UHFFFAOYSA-N
InChI=1S/C20H28I3N3O9/c1-25(3-10(31)7-29)19(34)12-14(21)13(20(35)26(2)4-11(32)8-30)16(23)17(15(12)22)24-18(33)9(5-27)6-28/h9-11,27-32H,3-8H2,1-2H3,(H,24,33)
| Molecular Formula | C20H28I3N3O9 |
| Molecular Weight | 835.1644 |
| Charge | 0 |
| Count |
|
| Stereochemistry | MIXED |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 2 |
| E/Z Centers | 0 |
| Optical Activity | UNSPECIFIED |
CNS Activity
Approval Year
Conditions
| Condition | Modality | Targets | Highest Phase | Product |
|---|---|---|---|---|
| Diagnostic | XENETIX Approved UseIntravenous urography, cerebral computed tomography, computed tomography of the whole body, digital subtraction angiography, arteriography, angiocardiography, venography, CT scan of the thorax. Launch Date1993 |
Doses
| Dose | Population | Adverse events |
|---|---|---|
102.5 mL single, intravascular Recommended Dose: 102.5 mL Route: intravascular Route: single Dose: 102.5 mL Sources: |
unknown, ADULT Health Status: unknown Age Group: ADULT Sex: M+F Food Status: UNKNOWN Sources: |
Disc. AE: Cardiac failure... AEs leading to discontinuation/dose reduction: Cardiac failure (grade 5, 0.002%) Sources: |
AEs
| AE | Significance | Dose | Population |
|---|---|---|---|
| Cardiac failure | grade 5, 0.002% Disc. AE |
102.5 mL single, intravascular Recommended Dose: 102.5 mL Route: intravascular Route: single Dose: 102.5 mL Sources: |
unknown, ADULT Health Status: unknown Age Group: ADULT Sex: M+F Food Status: UNKNOWN Sources: |
PubMed
| Title | Date | PubMed |
|---|---|---|
| Contrast-induced acute kidney injury in patients with renal dysfunction undergoing a coronary procedure and receiving non-ionic low-osmolar versus iso-osmolar contrast media. | 2010-01 |
|
| Nephrotoxicity of low-osmolar and iso-osmolar contrast media. | 2006-03 |
|
| Nephrotoxicity of low-osmolality versus iso-osmolality contrast agents: impact of N-acetylcysteine. | 2005-11 |
|
| Standard vs double dose of N-acetylcysteine to prevent contrast agent associated nephrotoxicity. | 2004-02 |
|
| A comparison of the efficacy and safety of ioxaglate and iobitridol in renal angioplasty. | 2000-05-05 |
Patents
| Substance Class |
Chemical
Created
by
admin
on
Edited
Mon Mar 31 18:05:01 GMT 2025
by
admin
on
Mon Mar 31 18:05:01 GMT 2025
|
| Record UNII |
182ECH14UH
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Preferred Name | English | ||
|
Official Name | English | ||
|
Systematic Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English |
| Classification Tree | Code System | Code | ||
|---|---|---|---|---|
|
WHO-ATC |
V08AB11
Created by
admin on Mon Mar 31 18:05:01 GMT 2025 , Edited by admin on Mon Mar 31 18:05:01 GMT 2025
|
||
|
NCI_THESAURUS |
C28500
Created by
admin on Mon Mar 31 18:05:01 GMT 2025 , Edited by admin on Mon Mar 31 18:05:01 GMT 2025
|
||
|
WHO-VATC |
QV08AB11
Created by
admin on Mon Mar 31 18:05:01 GMT 2025 , Edited by admin on Mon Mar 31 18:05:01 GMT 2025
|
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
IOBITRIDOL
Created by
admin on Mon Mar 31 18:05:01 GMT 2025 , Edited by admin on Mon Mar 31 18:05:01 GMT 2025
|
PRIMARY | |||
|
7040
Created by
admin on Mon Mar 31 18:05:01 GMT 2025 , Edited by admin on Mon Mar 31 18:05:01 GMT 2025
|
PRIMARY | |||
|
65985
Created by
admin on Mon Mar 31 18:05:01 GMT 2025 , Edited by admin on Mon Mar 31 18:05:01 GMT 2025
|
PRIMARY | |||
|
DTXSID90869865
Created by
admin on Mon Mar 31 18:05:01 GMT 2025 , Edited by admin on Mon Mar 31 18:05:01 GMT 2025
|
PRIMARY | |||
|
DB12407
Created by
admin on Mon Mar 31 18:05:01 GMT 2025 , Edited by admin on Mon Mar 31 18:05:01 GMT 2025
|
PRIMARY | |||
|
182ECH14UH
Created by
admin on Mon Mar 31 18:05:01 GMT 2025 , Edited by admin on Mon Mar 31 18:05:01 GMT 2025
|
PRIMARY | |||
|
SUB08205MIG
Created by
admin on Mon Mar 31 18:05:01 GMT 2025 , Edited by admin on Mon Mar 31 18:05:01 GMT 2025
|
PRIMARY | |||
|
C83821
Created by
admin on Mon Mar 31 18:05:01 GMT 2025 , Edited by admin on Mon Mar 31 18:05:01 GMT 2025
|
PRIMARY | |||
|
1449
Created by
admin on Mon Mar 31 18:05:01 GMT 2025 , Edited by admin on Mon Mar 31 18:05:01 GMT 2025
|
PRIMARY | |||
|
CHEMBL2107212
Created by
admin on Mon Mar 31 18:05:01 GMT 2025 , Edited by admin on Mon Mar 31 18:05:01 GMT 2025
|
PRIMARY | |||
|
31701
Created by
admin on Mon Mar 31 18:05:01 GMT 2025 , Edited by admin on Mon Mar 31 18:05:01 GMT 2025
|
PRIMARY | |||
|
m6322
Created by
admin on Mon Mar 31 18:05:01 GMT 2025 , Edited by admin on Mon Mar 31 18:05:01 GMT 2025
|
PRIMARY | Merck Index | ||
|
136949-58-1
Created by
admin on Mon Mar 31 18:05:01 GMT 2025 , Edited by admin on Mon Mar 31 18:05:01 GMT 2025
|
PRIMARY | |||
|
C093233
Created by
admin on Mon Mar 31 18:05:01 GMT 2025 , Edited by admin on Mon Mar 31 18:05:01 GMT 2025
|
PRIMARY | |||
|
100000083402
Created by
admin on Mon Mar 31 18:05:01 GMT 2025 , Edited by admin on Mon Mar 31 18:05:01 GMT 2025
|
PRIMARY | |||
|
87639
Created by
admin on Mon Mar 31 18:05:01 GMT 2025 , Edited by admin on Mon Mar 31 18:05:01 GMT 2025
|
PRIMARY | RxNorm |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
ACTIVE MOIETY |
|